-
1.发明授权Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases 有权使用尿激酶抑制剂治疗和/或预防神经病理学疾病公开(公告)号：US08093258B2
公开(公告)日：2012-01-10
申请号：US11922774
申请日：2006-06-22
申请人： Stefan Lorenzl , Wolfgang Schmalix
发明人： Stefan Lorenzl , Wolfgang Schmalix
摘要： The present invention relates to methods and compositions for the treatment and/or prevention of neuropathological and/or neurodegenerative diseases. In particular, the invention delivers novel uses of inhibitors of Urokinase-type Plasminogen activator in the treatment of amyotrophic lateral sclerosis.
摘要翻译： 本发明涉及用于治疗和/或预防神经病理学和/或神经变性疾病的方法和组合物。 特别地，本发明提供尿激酶型纤溶酶原激活物抑制剂在治疗肌萎缩性侧索硬化中的新用途。
-
公开(公告)号：US20070244127A1
公开(公告)日：2007-10-18
申请号：US11631891
申请日：2005-09-20
申请人： Wolfgang Schmalix , Markus Burgle , Klaus Koch
发明人： Wolfgang Schmalix , Markus Burgle , Klaus Koch
CPC分类号： A61K31/198 , A61K9/0019 , A61K31/18 , A61K31/495 , A61K47/10 , A61K47/12
摘要： The invention relates to improved and stable pharmaceutical formulations of phenylalanine derivatives and the use thereof as urokinase inhibitors, particularly for the treatment of malignant tumors and tumoral metastases.
摘要翻译： 本发明涉及苯丙氨酸衍生物的改进和稳定的药物制剂及其作为尿激酶抑制剂的用途，特别是用于治疗恶性肿瘤和肿瘤转移。
-
3.发明申请COMBINED TREATMENT OF CANCER BY UROKINASE INHIBITION AND A CYTOSTATIC ANTI-CANCER AGENT FOR ENHANCING THE ANTI-METASTATIC EFFECT 审中-公开通过尿激酶抑制联合治疗癌症和用于增强抗分化作用的CYTOSTATIC抗癌剂公开(公告)号：US20120165287A1
公开(公告)日：2012-06-28
申请号：US13411262
申请日：2012-03-02
IPC分类号： A61K31/7064 , A61P35/00 , A61P35/04 , A61K31/4965
CPC分类号： A61K31/505 , A61K31/165 , A61K31/175 , A61K31/4745 , A61K31/495 , A61K31/7068 , A61K39/39558 , A61K2300/00
摘要： The present invention relates to a combined treatment of cancer using a urokinase inhibitor and a cytotoxic or a cytostatic agent.
摘要翻译： 本发明涉及使用尿激酶抑制剂和细胞毒性或细胞生长抑制剂联合治疗癌症。
-
公开(公告)号：US07807681B2
公开(公告)日：2010-10-05
申请号：US12105975
申请日：2008-04-18
IPC分类号： A61K31/4965
CPC分类号： C07D295/185 , C07K5/06078 , C07K5/06191
摘要： The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.
摘要翻译： 本发明涉及用于抑制尿激酶纤溶酶原激活物（uPA）的新化合物，其具有高的生物利用度和口服施用性，并且还涉及作为用于治疗尿激酶或/和尿激酶受体相关疾病的治疗活性化合物的用途， 例如，肿瘤和转移。 本发明特别涉及含有羟基脒或羟基胍基团的化合物。
-
5.发明申请Use Of Urokinase Inhibitors for the Treatment and/or Prevention of Neuropathological Diseases 有权使用尿激酶抑制剂治疗和/或预防神经病理学疾病公开(公告)号：US20090069251A1
公开(公告)日：2009-03-12
申请号：US11922774
申请日：2006-06-22
申请人： Stefan Lorenzl , Wolfgang Schmalix
发明人： Stefan Lorenzl , Wolfgang Schmalix
摘要： The present invention relates to methods and compositions for the treatment and/or prevention of neuropathological and/or neurodegenerative diseases. In particular, the invention delivers novel uses of inhibitors of Urokinase-type Plasminogen activator in the treatment of amyotrophic lateral sclerosis.
摘要翻译： 本发明涉及用于治疗和/或预防神经病理学和/或神经变性疾病的方法和组合物。 特别地，本发明提供尿激酶型纤溶酶原激活物抑制剂在治疗肌萎缩性侧索硬化中的新用途。
-
公开(公告)号：US20080261998A1
公开(公告)日：2008-10-23
申请号：US12105975
申请日：2008-04-18
IPC分类号： A61K31/495 , A61P35/00 , A61P35/04
CPC分类号： C07D295/185 , C07K5/06078 , C07K5/06191
摘要： The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.
摘要翻译： 本发明涉及用于抑制尿激酶纤溶酶原激活物（uPA）的新化合物，其具有高的生物利用度和口服施用性，并且还涉及作为用于治疗尿激酶或/和尿激酶受体相关疾病的治疗活性化合物的用途， 例如，肿瘤和转移。 本发明特别涉及含有羟基脒或羟基胍基团的化合物。
-
公开(公告)号：US09089532B2
公开(公告)日：2015-07-28
申请号：US11631891
申请日：2005-09-20
申请人： Wolfgang Schmalix , Markus Bürgle , Klaus Koch
发明人： Wolfgang Schmalix , Markus Bürgle , Klaus Koch
IPC分类号： A61K31/495 , A61K31/198 , A61K9/00 , A61K31/18 , A61K47/10 , A61K47/12
CPC分类号： A61K31/198 , A61K9/0019 , A61K31/18 , A61K31/495 , A61K47/10 , A61K47/12
摘要： The invention relates to improved and stable pharmaceutical formulations of phenylalanine derivatives and the use thereof as urokinase inhibitors, particularly for the treatment of malignant tumors and tumoral metastases.
摘要翻译： 本发明涉及苯丙氨酸衍生物的改进和稳定的药物制剂及其作为尿激酶抑制剂的用途，特别是用于治疗恶性肿瘤和肿瘤转移。
-
8.发明申请Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect 审中-公开通过尿激酶抑制联合治疗癌症和用于增强抗转移作用的细胞抑制性抗癌剂公开(公告)号：US20080226624A1
公开(公告)日：2008-09-18
申请号：US12073693
申请日：2008-03-07
IPC分类号： A61K39/395 , A61K31/495 , A61K31/175 , A61K31/4745 , A61P35/00 , A61K31/7068 , A61K31/505 , A61K31/165
CPC分类号： A61K31/505 , A61K31/165 , A61K31/175 , A61K31/4745 , A61K31/495 , A61K31/7068 , A61K39/39558 , A61K2300/00
摘要： The present invention relates to a combined treatment of cancer using a urokinase inhibitor and a cytotoxic or a cytostatic agent.
摘要翻译： 本发明涉及使用尿激酶抑制剂和细胞毒性或细胞生长抑制剂联合治疗癌症。
-
公开(公告)号：US20060142305A1
公开(公告)日：2006-06-29
申请号：US11287480
申请日：2005-11-28
IPC分类号： A61K31/495
CPC分类号： C07D295/185 , C07K5/06078 , C07K5/06191
摘要： The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.
-
公开(公告)号：US20050181034A1
公开(公告)日：2005-08-18
申请号：US10521805
申请日：2003-07-22
IPC分类号： A61K9/127 , A61K31/495 , A61P35/00 , C07D295/18
CPC分类号： C07D295/18 , A61K9/127 , A61K31/495
摘要： The invention relates to pharmaceutical formulations of phenylalanine derivatives and to the use thereof as urokinase inhibitors, in particular for the treatment of malignant tumors and of tumor metastases.
摘要翻译： 本发明涉及苯丙氨酸衍生物的药物制剂及其作为尿激酶抑制剂的用途，特别是用于治疗恶性肿瘤和肿瘤转移。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.014 秒)
